Innovative Prostate Cancer Research Leads to New Opportunities in Care

As part of the Case Comprehensive Cancer Center here at University Hospitals, we lead a multi-disciplinary innovative prostate cancer research program from bench to bedside. Our research includes disruptive translational research involving artificial intelligence, genomics, non-invasive biomarkers, and novel imaging and biopsy platforms to improve the diagnosis, prognostication, and personalization of treatment. In addition, we lead and participate in a comprehensive array of clinical trials across the disease spectrum for men suspected of harboring prostate cancer, those with a newly diagnosed disease, to those that have progressed to more advanced disease states requiring the latest treatment options. Our research program aims to benefit all patients suffering from prostate cancer worldwide, but also a dedicated focus on reducing cancer health disparities in our local communities.

University Hospitals prostate cancer researchers are comprehensively funded through the NIH, DOD, PCF, PCORI, Damon Runyon Cancer Research Foundation, and the American Cancer Society.

The research team consistently publishes in the highest impact journals, including New England Journal of Medicine, Journal of the American Medical Association (JAMA), Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, Cell, Journal of Clinical Investigation, European Urology, Journal of Urology, Urology, Urologic Oncology, International Journal of Radiation Oncology, Biology, Physics, Prostate Cancer and Prostatic Diseases.

The team consists of international key opinion leaders across medical oncology, radiation oncology, and urologic oncology. We have leaders represented in the FDA, NCCN guidelines, NCI’s Genitourinary Steering Committee, Prostate Cancer Foundation, American Society for Radiation Oncology, American Urological Association, American Society of Clinical Oncology, NRG Oncology Group, and SWOG Cancer Research Network.